These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 35769466)

  • 1. Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.
    Yan D; Li W; Liu Q; Yang K
    Front Immunol; 2022; 13():914618. PubMed ID: 35769466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
    Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
    Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
    Richardson LG; Miller JJ; Kitagawa Y; Wakimoto H; Choi BD; Curry WT
    Neurosurg Focus; 2022 Feb; 52(2):E6. PubMed ID: 35104795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
    Friedrich M; Bunse L; Wick W; Platten M
    Curr Opin Oncol; 2018 Nov; 30(6):368-374. PubMed ID: 30102604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.
    Gonzalez N; Asad AS; Gómez Escalante J; Peña Agudelo JA; Nicola Candia AJ; García Fallit M; Seilicovich A; Candolfi M
    Expert Opin Ther Targets; 2021 Dec; 25(12):1045-1060. PubMed ID: 34904924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
    Picca A; Finocchiaro G
    Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells.
    Zhang L; Sorensen MD; Kristensen BW; Reifenberger G; McIntyre TM; Lin F
    Clin Cancer Res; 2018 Nov; 24(21):5381-5391. PubMed ID: 30006485
    [No Abstract]   [Full Text] [Related]  

  • 8. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
    Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
    Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
    Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
    Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
    Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
    Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapies for IDH-Mutant Gliomas.
    Alshiekh Nasany R; de la Fuente MI
    Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
    Wahl DR; Venneti S
    Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1.
    Cordner R; Jhun M; Panwar A; Wang H; Gull N; Murali R; McAbee JH; Mardiros A; Sanchez-Takei A; Mazer MW; Fan X; Jouanneau E; Yu JS; Black KL; Wheeler CJ
    Oncogene; 2023 Jun; 42(25):2088-2098. PubMed ID: 37161052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local and systemic effects of IDH mutations on primary glioma patients.
    Tang F; Wang DW; Xi C; Yang JZ; Liu ZY; Yu DH; Wang ZF; Li ZQ
    Immunology; 2023 Aug; 169(4):503-514. PubMed ID: 37054988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas.
    Friedrich M; Sankowski R; Bunse L; Kilian M; Green E; Ramallo Guevara C; Pusch S; Poschet G; Sanghvi K; Hahn M; Bunse T; Münch P; Gegner HM; Sonner JK; von Landenberg A; Cichon F; Aslan K; Trobisch T; Schirmer L; Abu-Sammour D; Kessler T; Ratliff M; Schrimpf D; Sahm F; Hopf C; Heiland DH; Schnell O; Beck J; Böttcher C; Fernandez-Zapata C; Priller J; Heiland S; Gutcher I; Quintana FJ; von Deimling A; Wick W; Prinz M; Platten M
    Nat Cancer; 2021 Jul; 2(7):723-740. PubMed ID: 35121943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
    Mo H; Magaki S; Deisch JK; Raghavan R
    J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
    Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
    Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.